Please assess the completion status of the following clinical trial:

Trial Title: A Clinical Study of the ACRYSOF® IQ EDF Intraocular Lens (IOL)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Able to understand and sign an Independent Ethics Committee (IEC)/ Institutional Review Board (IRB) approved Informed Consent Form;~* Diagnosed with cataract in both eyes;~* Planned cataract removal by routine small incision surgery;~* Calculated IOL power is within the clinical study supply range (18.0-25.0 diopter (D) in 0.5 D steps);~* Preoperative regular astigmatism of less than 1.0 D.~Exclusion Criteria:~* Pregnancy or lactation current or planned during the course of the study;~* History of anterior segment (corneal, anterior chamber, sulcus) or posterior segment (uveal, vitreo-retinal) pathology including retinal vascular occlusive disease, retinal detachment or peripheral retinal laser photocoagulation, age-related macular degeneration (ARMD), glaucoma (uncontrolled or controlled with medication) or ocular hypertension, diabetic retinopathy, retinitis pigmentosa and any optic nerve pathology.

- Gender: ALL
- Minimum Age: 22 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- DFT015 (Type: EXPERIMENTAL): ACRYSOF® IQ Extended Depth of Focus Intraocular lens (IOL), bilateral implantation
- SN60WF (Type: ACTIVE_COMPARATOR): ACRYSOF® IQ Monofocal IOL, bilateral implantation

Based on this trial design, predict the completion outcome and termination type (if applicable).